Cyclic peptides can cross the intestinal wall if designed to minimize exposed polarity while balancing size, flexibility, and fat-solubility — potentially enabling oral peptide pills.
3 design regimesPhysical property guidelines, macrocyclic ring strategies, and side chain strategies together form the framework for making cyclic peptides orally absorbable
What the researchers found
Cyclic peptides can achieve oral bioavailability despite violating traditional drug-likeness rules (Lipinski's Rule of 5), but they must be carefully designed for intestinal permeability. The key design principles fall into three categories: physical property guidelines (controlling size, flexibility, and lipophilicity), macrocyclic ring strategies (optimizing the backbone structure), and side chain strategies (minimizing solvent-exposed polarity).
The overarching goal is to reduce the peptide's exposure of polar chemical groups to the surrounding environment while keeping other properties in favorable ranges. This balancing act allows peptide chemists to achieve gut absorption alongside other critical drug properties like solubility and ability to bind their target.
Why it matters
Most peptide drugs must be injected because they can't survive the gut or cross the intestinal wall. This review lays out the design rules that are making oral peptide drugs possible — a development that could transform how peptide therapeutics are delivered. The success of oral semaglutide (Rybelsus) shows this isn't just theoretical; the design principles described here are actively enabling the next generation of oral peptide medicines.
The numbers in context
3 design regimes · beyond Rule-of-5 chemistry · minimize solvent-exposed polarity
How the study worked
Methods review covering design principles for intestinal permeability of cyclic peptides, including physical property guidelines, macrocyclic ring design strategies, and side chain optimization approaches developed in recent years.
Who was studied
Not applicable — methods review for peptide chemistry
What this study cannot tell us
This is a methods review focused on design principles rather than clinical validation. Achieving intestinal permeability in the lab doesn't guarantee oral bioavailability in humans, as other factors like metabolic stability and first-pass liver effects also play critical roles.
How to read the evidence
This is a methods review in Methods in Molecular Biology providing practical design guidance based on accumulated research. It synthesizes existing principles rather than presenting new experimental data.
When this study was published
Published in 2019 in Methods in Molecular Biology. The design principles remain foundational and current, though newer computational and AI-driven approaches have since expanded the toolkit.
The bigger picture
The pharmaceutical industry's biggest peptide challenge is oral delivery. Cyclic peptides occupy a unique 'beyond Rule-of-5' chemical space where traditional drug design rules don't apply. The design principles in this review represent the collective knowledge that's enabling companies to develop oral peptide drugs — from oral semaglutide to experimental cyclic peptide candidates targeting cancers and inflammatory diseases that were previously injectable-only.
Questions still open
- How well do these design principles translate from lab permeability assays to actual oral bioavailability in humans?
- Can these cyclic peptide design strategies be combined with absorption enhancers to achieve even higher oral bioavailability?
- What role does computational modeling play in predicting which cyclic peptide designs will have good intestinal permeability?
Common questions
Why can't most peptides be taken as pills?
What is the Rule of 5 and why do cyclic peptides break it?
Read the original research
Design Principles for Intestinal Permeability of Cyclic Peptides.
Methods in molecular biology (Clifton, N.J.), 2001, 1-15
Citation
Mathiowetz, Alan M. (2019). Design Principles for Intestinal Permeability of Cyclic Peptides.. Methods in molecular biology (Clifton, N.J.), 2001, 1-15. https://doi.org/10.1007/978-1-4939-9504-2_1